I was wondering if anyone remembers and had any thoughts on the fact that this big pharmacy consortium was put together shortly( at least announced, so most likely formed a little bit before) the sabotage of our Phase II trial, also interesting is how quickly the other big pharmas all of a sudden had immunotherapy in the forefront. Makes one wonder doesn't it. And we are surprised the share price is where it's at. I am sure there is no conspiracy theory there. I believe this was October 12, 2012
By Nick Taylor
A consortium of leading pharma companies has initiated a project to share historic clinical trial data to speed cancer research. The database--dubbed Project Data Sphere--will use security and anonymization strategies to overcome privacy fears related to sharing patient information.
Project Data Sphere is the brainchild of the CEO Roundtable on Cancer Life Sciences Consortium, which lists a host of Big Pharma companies, CROs and top academic centers as members. In combination, the members are sitting on a treasure trove of data from previous cancer trials that could accelerate development of new therapies.
[Webinar] How to Prepare Your Supply Chain for Emerging Markets' Novel Challenges
DATE: WEDNESDAY, SEPTEMBER 9TH | 11AM ET / 8AM PT
With biopharma companies hitching their long-term growth plans to success in emerging markets, they can ill-afford for logistical difficulties in new territories to scuttle their ambitions. This is a real risk, though. Transporting drugs to patients in Brazil, India and China is fraught with multiple challenges for which experience of shipping products in the West offers scant preparation. Register Now!
Sign up for our FREE newsletter for more news like this sent to your inbox!
Sanofi ($SNY) CEO Chris Viehbacher heads the consortium. "Broadly sharing existing clinical trial data for the benefit of all researchers can be a key driver in speeding up cancer research efforts, encouraging innovation, and honoring those patients who have participated in clinical trials," Viehbacher told PharmaTimes. Consortium member GlaxoSmithKline ($GSK) noted similar benefits when committing to share detailed trial data last week.
Access to a pool of historic data could improve population estimates for epidemiological work or allow for ready-made comparisons of different treatment regimens. Researchers have known of these potential benefits for years, but getting companies to share is tricky. Project Data Sphere began taking shape two years ago, PharmaTimes reports, but a formal launch is still months away. Spring 2013 is the current expectation.
In the past, concerns about giving away competitive advantages or violating patient privacy have held the idea back. Advances in data security and anonymization have helped overcome some of these fears. But there is also a recognition that something needs to change if pharma is to make major advances in treating cancer.
"It's taking $2 billion or more to bring a drug to market. At the same time, we've got about the same number of people dying from cancer that we did 30 to 40 years ago. We have got to get more innovative in how we develop cancer drugs," Sanofi oncology VP Charles Hugh-Jones said.
- here's PharmaTimes' article
- get more in the press release
- read Science's take
Related Articles:
GSK's transparency pledge could be a boon to drug researchers
Glaxo pledges to unveil all trial data, good, bad or ugly
Sign Up for FierceBiotechIT!
